Variables | Frequency | Percent | |
---|---|---|---|
Age | 18–29 | 54 | 12.8 |
30–39 | 169 | 40.0 | |
40–49 | 136 | 32.2 | |
> = 50 | 64 | 15.1 | |
Marital status | Single | 97 | 22.9 |
Married | 209 | 49.4 | |
Divorced | 81 | 19.1 | |
Widowed | 36 | 8.5 | |
Gender | Female | 272 | 64.3 |
Male | 151 | 35.7 | |
Resident | Urban | 343 | 81.1 |
Rural | 80 | 18.9 | |
Occupation | Farmer | 51 | 12.1 |
Merchant | 58 | 13.7 | |
Student | 17 | 4 | |
government employ | 43 | 10.2 | |
daily laborer | 62 | 14.7 | |
house life | 101 | 23.9 | |
Private employ | 66 | 15.6 | |
Other | 25 | 5.9 | |
Educational status | Illiterate | 121 | 28.6 |
primary school | 117 | 27.7 | |
secondary school | 142 | 33.6 | |
Tertiary | 43 | 10.2 | |
Religion | Orthodox | 386 | 91.3 |
Muslim | 30 | 7.1 | |
Protestant | 7 | 1.7 | |
Total | 423 | 100.0 | |
Duration of ART in year | <=6 | 162 | 38.3 |
> 6 | 261 | 61.7 | |
Mean ART duration in year | 7 year (+ 3) | 423 | 100% |
Base line WHO stage | WHO stage I | 57 | (13.5) |
WHO stage II | 97 | (22.9) | |
WHO stage III | 214 | (50.6) | |
WHO stage IV | 55 | (13.0) | |
WHO stage during data collection | WHO stage I | 11 | (2.6) |
WHO stage II | 408 | (96.5) | |
WHO stage III | 4 | (.9) | |
Type of Opportunistic infection | No | 308 | (72.8) |
Protozoa | 4 | (.9) | |
Helminths | 12 | (2.8) | |
Hepatitis viruses | 3 | (.7) | |
fungal infections | 1 | (.2) | |
TB | 89 | (21.0) | |
Mixed | 6 | (1.4) | |
Initial regimen | D4T + 3TC + NVP | 78 | (18.4) |
D4T + 3TC+ EFV | 29 | (6.9) | |
AZT +3TC + NVP | 156 | (36.9) | |
AZT + 3TC + EFV | 30 | (7.1) | |
TDF + 3TC + EFV | 87 | (20.6) | |
TDF + 3TC + NVP | 31 | (7.3) | |
D4T + 3TC + NVP | 6 | (1.4) | |
Pediatric 4C (AZT + 3TC + NVP) | 6 | (1.4) | |
Switching | No | 261 | (61.7) |
Yes | 162 | (38.3) | |
Total | 423 | (100.0) | |
Switching | To 1st line drug | 150 | (35.5) |
To 2nd line drug | 12 | (2.8) | |
Second regimen | AZT +3TC + NVP | 61 | 37.7 |
AZT + 3TC + EFV | 25 | 15.4 | |
TDF + 3TC + NVP | 25 | 15.4 | |
TDF + 3TC + EFV | 39 | 24.1 | |
ABC + ddl + LPV/R | 11 | 6.8 | |
TDF + ddl + IPV/R | 1 | .6 | |
Reason of switching drug | Toxicity | 109 | (67.3) |
Pregnancy | 7 | (4.3) | |
TB | 18 | (11.1) | |
Clinical failure | 1 | (.6) | |
Age | 9 | (5.6) | |
ARV drug ADH at base line | Good | 408 | (96.5) |
Fair | 2 | (.5) | |
Poor | 13 | (3.1) | |
ARV drug ADH During data collection | Good | 420 | (99.3) |
Poor | 3 | (.7) | |
Base line CD4 count | <=199 | 267 | (63.1) |
200–349 | 120 | (28.4) | |
350–499 | 27 | (6.4) | |
> = 500 | 9 | (2.1) | |
CD4 count during data collection | <=199 | 44 | (10.4) |
200–349 | 110 | (26.0) | |
350–499 | 114 | (27.0) | |
> = 500 | 155 | 36.6 | |
Viral load count | Undetected | 224 | 53.0 |
0–19 | 84 | 19.9 | |
20–999 | 53 | 12.5 | |
> = 1000 | 62 | 14.7 | |
Total | 423 | 100 | |
Component of immunological failure | CD4 Falling More Than 50% | 30 | 53.6 |
CD4 Falling Below Baseline | 21 | 37.5 | |
CD4 Persistently Below 100 | 5 | 8.9 | |
Total | 56 | 100 |